Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 5/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19519903 | 1.00 | ACE2 (0.41) | ACE2PAOXEPHX1DPP7SLC15A1 | |
| SCHEMBL18085370 | 1.00 | ACE2 (0.41) | ACE2PAOXEPHX1DPP7SLC15A1 | |
| SCHEMBL19519901 | 0.94 | ACE2 (0.48) | ACE2PAOXEPHX1DPP7CA1 | |
| SCHEMBL19520052 | 0.94 | ACE2 (0.48) | ACE2PAOXEPHX1DPP7CA1 | |
| SCHEMBL11397604 | 0.92 | ACE2 (0.52) | ACE2EPHX1CA1ZDHHC7MAPK1 | |
| SCHEMBL8436494 | 0.87 | TSHR (0.42) | PAOXEPHX1ZDHHC7MAPK1KDM4E | |
| SCHEMBL22539051 | 0.86 | PLA2G2C (0.39) | ACE2PAOXEPHX1DPP7SLC15A1 | |
| SCHEMBL14094259 | 0.83 | KDM4E (0.54) | PAOXEPHX1ZDHHC7MAPK1KDM4E | |
| SCHEMBL16360403 | 0.83 | CYP2D6 (0.52) | ACE2EPHX1DPP7SLC15A1CA2 | |
| SCHEMBL11077957 | 0.83 | CYP2D6 (0.52) | ACE2EPHX1DPP7SLC15A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759109-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3722297-A1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | Gilead Sciences, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3321265-B1 | 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR UTILISATION AS MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES INC (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019040102-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| EP-3321265-A1 | 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR UTILISATION AS MODULATORS OF TOLL-LIKE RECEPTORS | Gilead Sciences, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3097102-B1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2017048727-A1 | MODULATORS OF TOLL-LIKE RECPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-8436207-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | ACE2 2888/4885PAOX 1319/4885EPHX1 3828/4885 |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | ACE2 2888/4885PAOX 1319/4885EPHX1 3828/4885 |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | HAX1, PRDX1, APOL1 | ACE2 3342/4885PAOX 14/4885EPHX1 181/4885 |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR8, TLR3, TLR6 | ACE2 3006/4885PAOX 3381/4885EPHX1 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.